Aquestive Therapeutics to present new findings at AAAAI meeting

Aquestive Therapeutics (AQST) announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology, AAAAI, Annual Meeting. The meeting will take place February 28 – March 3, 2025, in San Diego, CA. In the Phase 2 open-label Oral Anaphylm Symptom Intervention Study (“OASIS”) study, adults with Oral Allergy Syndrome received Anaphylm under different conditions, including single and repeat dosing with and without oral allergen challenge, alongside intramuscular (IM) epinephrine injection as a comparator. The study found that: Anaphylm matched or exceeded IM epinephrine in all key PK parameters. No significant differences in drug performance compared to IM epinephrine were observed, regardless of whether patients had an oral allergen challenge or not. Median symptom resolution time was 12 minutes compared to 74 minutes without treatment; mean angioedema symptom resolution time was within 5 minutes.